Bioequivalence of a New and a Commercial Alprazolam Sublingual Formulation

• Status: Withdrawn
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study tests the hypothesis that the bioavailability of alprazolam from a new sublingual formulation is the same as that from an existing sublingual formulation.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Alprazolam

Criteria

Inclusion Criteria:

• healthy male or female subjects

• BMI 18 to 26.9

• must give informed consent

Exclusion Criteria:

• clinically significant disease

• narrow angle glaucoma

• positive drug screen